The collaboration stated that the financings help to advance innovative precision therapy pipeline through internal R&D & strategic business development along with the launch of Ayvakit/Ayvakyt & Gavreto
Blueprint will receive $250M up front from Sixth Street for future royalties from Ayvakit & BLU-263 at a rate of 9.75% with an annual cap of $900M in net sales & cumulative cap of 1.45 times the invested capital; $150M of a $400M senior secured credit facility will be drawn by Blueprint initially with the remaining $250M in delayed draw tranches at Blueprint’s election; $260M credit facility for buy-side business development opportunities
Royalty pharma has acquired an Ex-US royalty on Roche’s sales of Gavreto (Ex- greater China) & Blueprint to receive $575M incl. $175M up front & $165M in milestones on future sales. Gavreto has been submitted for marketing approval for thyroid cancers in the EU with an expected decision in H2’22
Ref: PR Newswire | Image: Blueprint
